General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Eye care

Alcon discovery and development efforts begin and end with the patient. Alcon’s global research and development team of more than 2,000 highly skilled individuals is developing a full range of eye care products and solutions across our three businesses. Based on the unmet medical needs of today – and tomorrow – Alcon is currently developing products and solutions to address:

  • Cataracts
  • Glaucoma
  • Retinal diseases
  • Age-related macular degeneration (AMD)
  • Dry eye
  • Refractive errors
  • Ocular allergies
  • Dry eye
  • Infection and inflammation

Alcon invests more than $1 billion annually in research and development to deliver innovations that solve unmet patient needs. Alcon’s commitment to research and development is unparalleled in the private sector.

Research capacity

Alcon discovers and develops innovative eye care treatments based on unmet patient needs and a strong scientific understanding of eye diseases and conditions, with a focused pipeline that aligns with our three businesses – Surgical, Pharmaceutical and Vision Care.

Alcon relies on its R&D organization and relationships with clinicians around the world to conduct large-scale clinical trials. Working closely with clinical groups, the Alcon teams ensure that development efforts meet the needs of doctors and their patients as well as those of regulatory bodies worldwide.

Catatacts: a leading cause of preventable blindness

Cataracts are a leading cause of preventable blindness in all regions of the world; 51% or more than 20 million people have cataracts. A cataract occurs when the eye’s lens becomes cloudy and prevents the passage of light to the retina, impairing and disrupting vision. Although a treatable disease, most cataracts are age-related and are a normal part of aging. Cataracts can be successfully corrected with surgery, helping restore a patient’s vision and is one of the most cost-effective medical procedures restoring vision in millions of people. Unfortunately, millions of patients in the developing world lose their sight due to lack of proper treatment. Alcon is committed to enhancing access to treatment of cataracts, working through humanitarian efforts, education on a local level and product support.

The Alcon difference

As a world leader in eye care, the Alcon Division of Novartis has played a unique role in the evolution of cataract surgery. Alcon was a driving force behind the adoption of phacoemulsification, a procedure in which an ultrasonic device is used to remove a cataractous lens. Alcon scientists also led in the development of foldable intraocular lenses that, along with phacoemulsification, have enabled surgeons to reduce the size of incisions, speed up recovery times, and improve patient outcomes.